Copyright
©The Author(s) 2015.
World J Hepatol. Jan 27, 2015; 7(1): 1-6
Published online Jan 27, 2015. doi: 10.4254/wjh.v7.i1.1
Published online Jan 27, 2015. doi: 10.4254/wjh.v7.i1.1
Target | Name | Content | Vendor | Current status |
MiR34 | MRX34 | Liposome-formulated miR-34 mimic | Mirna Therapeutics | Phase I |
VEGF/KSP | ALN-VSP | RNAi targeting VEGF/KSP | Alnylam Pharmaceuticals | Phase I |
PLK1 | TMK-PLK1 | RNAi targeting PLK1 | Tekmira Pharmaceuticals | Phase I/II |
MiR21 | Anti-miR21 | Antisense against miR21 | Regulus Therapeutics | Preclinical |
MiR221 | Anti-miR221 | Antisense against miR221 | Regulus Therapeutics | Preclinical |
MiR7 | MiR7 mimic | MiR7 mimic | MiReven | Preclinical |
- Citation: Shibata C, Otsuka M, Kishikawa T, Ohno M, Yoshikawa T, Takata A, Koike K. Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma. World J Hepatol 2015; 7(1): 1-6
- URL: https://www.wjgnet.com/1948-5182/full/v7/i1/1.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i1.1